KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Liabilities and Shareholders Equity: 2013-2024

Historic Liabilities and Shareholders Equity for Xenon Pharmaceuticals (XENE) over the last 11 years, with Dec 2024 value amounting to $798.1 million.

  • Xenon Pharmaceuticals' Liabilities and Shareholders Equity fell 27.28% to $607.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year decrease of 21.65%. This contributed to the annual value of $798.1 million for FY2024, which is 17.27% down from last year.
  • According to the latest figures from FY2024, Xenon Pharmaceuticals' Liabilities and Shareholders Equity is $798.1 million, which was down 17.27% from $964.8 million recorded in FY2023.
  • In the past 5 years, Xenon Pharmaceuticals' Liabilities and Shareholders Equity registered a high of $964.8 million during FY2023, and its lowest value of $189.2 million during FY2020.
  • For the 3-year period, Xenon Pharmaceuticals' Liabilities and Shareholders Equity averaged around $839.0 million, with its median value being $798.1 million (2024).
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Liabilities and Shareholders Equity surged by 202.35% in 2021, and later fell by 17.27% in 2024.
  • Over the past 5 years, Xenon Pharmaceuticals' Liabilities and Shareholders Equity (Yearly) stood at $189.2 million in 2020, then surged by 202.35% to $572.0 million in 2021, then soared by 31.84% to $754.1 million in 2022, then grew by 27.93% to $964.8 million in 2023, then declined by 17.27% to $798.1 million in 2024.